TIDMHCM

RNS Number : 6557G

Hutchison China Meditech Limited

27 November 2020

Notification of Dilution of Voting Rights

London: Friday, November 27, 2020: Hutchison China MediTech Limited (" Chi-Med ") (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (" CK Hutchison ") shareholding([1]) in Chi-Med remains unchanged, at 332,478,770 ordinary shares of par value US$0.10 each in the capital of Chi-Med ("Shares").

Each American Depositary Share ("ADS") represents five Shares. As announced on November 17, 2020, Chi-Med issued a total of 16,666,670 Shares (equivalent to 3,333,334 ADSs) to Canada Pension Plan Investment Board. Chi-Med was notified on November 26 , 2020 that this issuance diluted CK Hutchison's holding([1]) to 45.69 per cent of the total number of voting rights of Chi-Med. The date on which the notification threshold was crossed was November 26, 2020.

([1]) Held through CK Hutchison's indirect wholly-owned subsidiary Hutchison Healthcare Holdings Limited.

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com .

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President                            +852 2121 8200 
  Annie Cheng, Vice President                                +1 (973) 567 3786 
 
Media Enquiries 
  Americas - Brad Miles, Solebury Trout                      +1 (917) 570 7340 (Mobile) 
                                                              bmiles@troutgroup.com 
  Europe - Ben Atwell / Alex Shaw, FTI Consulting            +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 
                                                             545 055 (Mobile) 
                                                             Chi-Med@fticonsulting.com 
  Asia - Joseph Chi Lo / Zhou Yi, Brunswick                  +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 97 
                                                             83 6894 (Mobile), y zhou@brunswickgroup.com 
 
Nominated Advisor 
  Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) 
   Limited                                                   +44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRUNVURRUUAUAA

(END) Dow Jones Newswires

November 27, 2020 02:00 ET (07:00 GMT)

Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Hutchison China Meditech Charts.
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Hutchison China Meditech Charts.